The ShORe trial aims to determine if the investigational medication OPT-302 will improve vision for people with wet age-related macular degeneration (AMD) when given in combination with ranibizumab, compared to ranibizumab alone.
About this study
Age-related macular degeneration (AMD) is an eye condition that can cause blurry vision or dark spots when looking straight ahead. Wet AMD occurs when abnormal blood vessels grow under the macula and retina, a part of the eye that helps to see. The abnormal blood vessels leak blood and fluid, causing problems with vision.
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.
The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.
The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.